KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Revenue: 2011-2025

Historic Revenue for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $192.1 million.

  • Supernus Pharmaceuticals' Revenue rose 9.34% to $192.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $681.5 million, marking a year-over-year increase of 4.54%. This contributed to the annual value of $661.8 million for FY2024, which is 8.94% up from last year.
  • Supernus Pharmaceuticals' Revenue amounted to $192.1 million in Q3 2025, which was up 16.11% from $165.5 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Revenue registered a high of $192.1 million during Q3 2025, and its lowest value of $130.9 million during Q1 2021.
  • In the last 3 years, Supernus Pharmaceuticals' Revenue had a median value of $164.3 million in 2023 and averaged $161.5 million.
  • In the last 5 years, Supernus Pharmaceuticals' Revenue skyrocketed by 37.86% in 2021 and then declined by 20.28% in 2023.
  • Supernus Pharmaceuticals' Revenue (Quarterly) stood at $159.1 million in 2021, then rose by 5.20% to $167.3 million in 2022, then fell by 1.80% to $164.3 million in 2023, then grew by 5.99% to $174.2 million in 2024, then rose by 9.34% to $192.1 million in 2025.
  • Its Revenue was $192.1 million in Q3 2025, compared to $165.5 million in Q2 2025 and $149.8 million in Q1 2025.